<DOC>
	<DOC>NCT01972204</DOC>
	<brief_summary>The purpose of this study is to examine the influence of the instruction on the use of Aricept with educational brochure on the 48-week medication persistence and to assess the reasons for discontinuation.</brief_summary>
	<brief_title>Intensive Instruction on the Use of Aricept</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Diagnostic evidence of probable Alzheimer's type Dementia consistent with DSMIV. Written informed consent will be obtained from subject (if possible) or from the subject's legal guardian or other representative (according to Japanese regulations as appropriate) prior to beginning screening activities. Patients having caregivers who submit written consent for cooperative involvement in this study, can provide patients' information necessary for this study, assist treatment compliance, and escort patients on required visits to study institution. Outpatients in their own home. Patients treated with donepezil, galantamine, rivastigmine in 4 weeks immediately before enrollment. Known hypersensitivity to donepezil or piperidine derivatives. Involvement in any other investigational drug clinical trail during the preceding 12 weeks.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>